Opinion

Video

Clinical Impact of ALK Inhibitor Data: Efficacy, Brain Metastases, and CNS Management Strategies

Author(s):

Balazs Halmos, MD,Julia Rotow, MD

Panelists discuss how recent data influence treatment choices for ALK-positive NSCLC patients, highlighting specific patient factors that guide decisions and potential concerns regarding the use of lorlatinib as first-line therapy.

  1. Dr Gadgeel: How do these data impact your treatment choice for your patients?
  2. What specific patient factors would influence your decision between treatment options? What concerns might prevent you from choosing lorlatinib as a first-line treatment?
Related Videos
Related Content